Evidence map›Paper›PMID 41415563›Full record

ArticleFrontiers in pharmacology2025

Farrerol inhibits proliferation and migration of colorectal cancer via the VEGF signaling pathway: evidence from network pharmacology, molecular docking, molecular dynamics simulation, and

Longhui Zhang, Qijing Xu, Guanduo Sun, Xiaokang Zhang, Jialong Xue, Chun Yao, Dechun Liu, Jingming Zhai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Longhui ZhangThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Qijing XuThe Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Guanduo SunThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Xiaokang ZhangThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Jialong XueThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Chun YaoThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Dechun LiuThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Jingming ZhaiThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Although farrerol exhibits promising antitumor properties against various cancers, its potential therapeutic effects on colorectal cancer (CRC) remain unexplored, and the underlying mechanisms are still unclear. Based on network pharmacology, molecular docking, molecular dynamics simulations, and Methods: This study employed network pharmacology to screen for potential therapeutic targets and pathways of farrerol in CRC, followed by preliminary validation of target validity through molecular docking and molecular dynamics simulations. Finally, Results: Network pharmacology identified 12 key targets: CCNA1, CCNA2, CCNE1, CDC25B, CDK2, CYP19A1, ESR1, ESR2, HSP90AA1, PTPN1, RAF1, and SRC. The molecular docking results revealed that the binding energies of farrerol with all target proteins were as follows: farrerol-CCNA1 (-8.6 kcal·mol Conclusion: This study, for the first time, validated the antitumor effect of farrerol against CRC through network pharmacology, molecular docking, molecular dynamics simulations, and

Indexed as

colorectal cancerfarrerolmolecular dockingmolecular mechanismnetwork pharmacology

Identifiers

PMID41415563
PMCPMC12708557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.